InfezMed - Antibacterial therapy - Antibacterial therapy

Antibacterial therapy

Valutazione di impatto economico dell’impiego di dalbavancina nel trattamento delle ABSSSI

Ercole Concia, Franco Ancona, Alessandro Miliacca

Le Infezioni in Medicina, Suppl. n. 1, 3-19, 2017

Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents

Angie M. Jarrad, Tomislav Karoli, Mark A. T. Blaskovich, Dena Lyras, Matthew A. Cooper

J. Med. Chem. 2015, 58, 5164−5185

When should acute exacerbations of COPD be treated with systemic corticosteroids and antibiotics in primary care: a systematic review of current COPD guidelines

Johanna Laue, Eirik Reierth and Hasse Melbye

Primary Care Respiratory Medicine (2015) 25, 15002; doi:10.1038/npjpcrm.2015.

Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge

Magnus Unemo

Unemo BMC Infectious Diseases (2015) 15:364

2015, Dalbavancin for treatment of SSTI, Ramdeen, EXp Op Inf Dis

Sheena Ramdeen, and Helen W Boucher

Expert Opin Pharmacother. 2015 September ; 16(13): 2073–2081.

Empiric therapy for hospital-acquired, Gram negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

Yoav Golan

BMC Infectious Diseases (2015) 15:313

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection

George G Zhanel, Andrew J Walkty, and James A Karlowsky

Can J Infect Dis Med Microbiol, 26, 6,2015

A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity

Xiuzhen Dia, Nan Baia,, Xin Zhangb, Bin Liub, Wentao Nib, et al.

Brazil. Infect. Dis. 2015,19, (4): 339-349

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review

Joumana Kmeid, Zeina A Kanafani

Core Evidence 2015:10 39–47

Novel antibiotics: Are we still in the pre–post‑antibiotic era?

R. Draenert, U. Seybold, E. Grützner, J. R. Bogner

Infection (2015) 43:145–151

2015, Procalcitonis and antibiotic therapy duration, Pantelidou, IJAA

Iliana-Maria Pantelidou, Evangelos J. Giamarellos-Bourboulis4th

International Journal of Antimicrobial Agents 46 (2015) S10–S12

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections

Marion J Skalweit

Drug Design, Development and Therapy 2015:9 2919–2925

Physicians’ attitudes and knowledge concerning antibiotic prescription and resistance: questionnaire development and reliability

António Teixeira Rodrigues, Mónica Ferreira, Fátima Roqueet al.

BMC Infectious Diseases (2016) 16:7

Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections A Systematic Review and Meta-Analysis

Wentao Ni, Yuliang Han, Jie Liu, Chuanqi Wei, Jin Zhao, et al.

Medicine _ Volume 95, Number 11, March 2016

Use of macrolides in lung diseases: recent literature controversies

Luiz Vicente Ribeiro Ferreira da Silva Filhoa,b, Leonardo Araujo Pintoc,d, Renato T. Steinc

J Pediatr (Rio J). 2015;91(6 Suppl 1):S52---S60

The use of prophylactic vancomycin to prevent MRSA colonization: does this double-edged sword promote future vancomycin resistance or is it a safe preventative strategy that should be used in all patients in the context of MRSA endemicity?

Li Bassi G, Saucedo LM.

Minerva Anestesiol. 2010 Mar;76(3):175-7.